Key Insights

Highlights

Success Rate

71% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

6.9%

2 terminated out of 29 trials

Success Rate

71.4%

-15.1% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed with results

Key Signals

3 with results71% success

Data Visualizations

Phase Distribution

27Total
Not Applicable (4)
Early P 1 (1)
P 1 (5)
P 2 (15)
P 3 (2)

Trial Status

Recruiting7
Unknown6
Not Yet Recruiting6
Completed5
Terminated2
Suspended1

Trial Success Rate

71.4%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT07099547Phase 2RecruitingPrimary

Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma

NCT04924062Phase 3CompletedPrimary

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

NCT04003636Phase 3CompletedPrimary

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

NCT05123482Phase 1Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT06048133Phase 2RecruitingPrimary

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

NCT05668884Phase 2RecruitingPrimary

GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

NCT07285044Phase 2Recruiting

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT02151084Phase 2Active Not RecruitingPrimary

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

NCT07062328Phase 2Not Yet RecruitingPrimary

A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC

NCT06168292Not ApplicableRecruitingPrimary

Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma

NCT06699459Phase 2Not Yet RecruitingPrimary

Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC

NCT06199882Phase 2SuspendedPrimary

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

NCT04003896Phase 2TerminatedPrimary

A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma

NCT06349044Not ApplicableRecruiting

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

NCT04067960Early Phase 1Completed

Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer

NCT06530823Phase 2Not Yet RecruitingPrimary

Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

NCT06463548Not ApplicableNot Yet RecruitingPrimary

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

NCT06430827Phase 2Not Yet RecruitingPrimary

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

NCT05845554UnknownPrimary

Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma

NCT06047990Not ApplicableUnknownPrimary

Endobiliary Percutaneous Cryobiopsy in Malignant Biliary Obstruction

Scroll to load more

Research Network

Activity Timeline